These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 26566803)

  • 1. Natural products against hematological malignancies and identification of their targets.
    Xu Y; Liu J; Wu Y; Guo Q; Sun H; Chen G
    Sci China Life Sci; 2015 Dec; 58(12):1191-201. PubMed ID: 26566803
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oridonin, a promising antitumor natural product in the chemotherapy of hematological malignancies.
    Zhao Z; Chen Y
    Curr Pharm Biotechnol; 2014; 15(11):1083-92. PubMed ID: 25391243
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The remarkable structural diversity achieved in ent-Kaurane Diterpenes by fungal biotransformations.
    Takahashi JA; Gomes DC; Lyra FH; Dos Santos GF; Martins LR
    Molecules; 2014 Feb; 19(2):1856-86. PubMed ID: 24518806
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Xanthones and Cancer: from Natural Sources to Mechanisms of Action.
    Klein-Júnior LC; Campos A; Niero R; Corrêa R; Vander Heyden Y; Filho VC
    Chem Biodivers; 2020 Feb; 17(2):e1900499. PubMed ID: 31794156
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recent advances in natural products from plants for treatment of liver diseases.
    Zhang A; Sun H; Wang X
    Eur J Med Chem; 2013 May; 63():570-7. PubMed ID: 23567947
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Exploring therapeutic potentials of baicalin and its aglycone baicalein for hematological malignancies.
    Chen H; Gao Y; Wu J; Chen Y; Chen B; Hu J; Zhou J
    Cancer Lett; 2014 Nov; 354(1):5-11. PubMed ID: 25128647
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Discovery and development of natural product oridonin-inspired anticancer agents.
    Ding Y; Ding C; Ye N; Liu Z; Wold EA; Chen H; Wild C; Shen Q; Zhou J
    Eur J Med Chem; 2016 Oct; 122():102-117. PubMed ID: 27344488
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Diterpenoid lead stevioside and its hydrolysis products steviol and isosteviol: Biological activity and structural modification.
    Wang M; Li H; Xu F; Gao X; Li J; Xu S; Zhang D; Wu X; Xu J; Hua H; Li D
    Eur J Med Chem; 2018 Aug; 156():885-906. PubMed ID: 30059803
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of Non Receptor Tyrosine Kinases in Hematological Malignances and its Targeting by Natural Products.
    Siveen KS; Prabhu KS; Achkar IW; Kuttikrishnan S; Shyam S; Khan AQ; Merhi M; Dermime S; Uddin S
    Mol Cancer; 2018 Feb; 17(1):31. PubMed ID: 29455667
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Icaritin: A Novel Natural Candidate for Hematological Malignancies Therapy.
    Yang XJ; Xi YM; Li ZJ
    Biomed Res Int; 2019; 2019():4860268. PubMed ID: 31032347
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Opportunities and Challenges for Natural Products as Novel Antituberculosis Agents.
    Farah SI; Abdelrahman AA; North EJ; Chauhan H
    Assay Drug Dev Technol; 2016; 14(1):29-38. PubMed ID: 26565779
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Progress in research of the structural optimization of natural product-like Garcinia caged xanthones].
    Wang YY; Zhang XJ; Yang YR; Sun HP; You QD
    Yao Xue Xue Bao; 2014 Mar; 49(3):293-302. PubMed ID: 24961098
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Stevioside and related compounds: therapeutic benefits beyond sweetness.
    Roberts A; Munro I
    Pharmacol Ther; 2009 Jun; 122(3):e1-2; author reply e3. PubMed ID: 19344740
    [No Abstract]   [Full Text] [Related]  

  • 14. EPHA3 as a novel therapeutic target in the hematological malignancies.
    Keane N; Freeman C; Swords R; Giles FJ
    Expert Rev Hematol; 2012 Jun; 5(3):325-40. PubMed ID: 22780212
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecular targets of gambogic acid in cancer: recent trends and advancements.
    Kashyap D; Mondal R; Tuli HS; Kumar G; Sharma AK
    Tumour Biol; 2016 Oct; 37(10):12915-12925. PubMed ID: 27448303
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MDM2/X inhibitors under clinical evaluation: perspectives for the management of hematological malignancies and pediatric cancer.
    Tisato V; Voltan R; Gonelli A; Secchiero P; Zauli G
    J Hematol Oncol; 2017 Jul; 10(1):133. PubMed ID: 28673313
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The potential of secondary metabolites from plants as drugs or leads against protozoan neglected diseases - part II.
    Schmidt TJ; Khalid SA; Romanha AJ; Alves TM; Biavatti MW; Brun R; Da Costa FB; de Castro SL; Ferreira VF; de Lacerda MV; Lago JH; Leon LL; Lopes NP; das Neves Amorim RC; Niehues M; Ogungbe IV; Pohlit AM; Scotti MT; Setzer WN; de N C Soeiro M; Steindel M; Tempone AG
    Curr Med Chem; 2012; 19(14):2176-228. PubMed ID: 22414104
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Is dual inhibition of metalloenzymes HDAC-8 and MMP-2 a potential pharmacological target to combat hematological malignancies?
    Amin SA; Adhikari N; Jha T
    Pharmacol Res; 2017 Aug; 122():8-19. PubMed ID: 28501516
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bioactivity Profile of the Diterpene Isosteviol and its Derivatives.
    Ullah A; Munir S; Mabkhot Y; Badshah SL
    Molecules; 2019 Feb; 24(4):. PubMed ID: 30769819
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Proteomic identification of proteins involved in the anticancer activities of oridonin in HepG2 cells.
    Wang H; Ye Y; Pan SY; Zhu GY; Li YW; Fong DW; Yu ZL
    Phytomedicine; 2011 Jan; 18(2-3):163-9. PubMed ID: 20724128
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.